Table 4.
Summary of trials highlighting the effects of oral hypoglycemic agents and CB1 receptor blockade on atherosclerosis. progression.
| Study | N | Medication | Imaging modality | Follow-up (months) | Outcome | Result | P-value |
|---|---|---|---|---|---|---|---|
| PERISCOPE [68] | 543 | Pioglitazone versus Glimipride | IVUS | 18 | Δ PAV (%) | −0.16 versus +0.73 | .002 |
|
| |||||||
| CHICAGO [69] | 462 | Pioglitazone versus Glimipride | B-ultrasound | 18 | Δ CIMT (mm) | +0.012 versus −0.001 | .02 |
|
| |||||||
| STRADUVARIUS [67] | 839 | CB1-blockade (Rimonabant) | IVUS | 18 | Δ PAV (%) | +0.25 versus +0.51 | .22 |
| Δ total atheroma volume (mm3) | −2.2 versus +0.88 | .03 | |||||